For suspected or existing coronary artery disease. ANDA 203783, held by Brigham Womens Hosp. Ammonia N-13.
As of Nov 16, 2026, ANDA 203783 (Ammonia N 13), held by Brigham Womens Hosp, was first approved by FDA on Oct 30, 2014, with 1 approved supplement and 0 published complete response letters.
Ammonia N 13 Injection is indicated for diagnostic Positron Emission Tomography (PET) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease. Ammonia N 13 Injection is a radioactive diagnostic agent for Positron Emission Tomography (PET) indicated for diagnostic PET imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 30, 2014 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ammonia N 1330mCi-300mCi/8ML (3.75-37.5mCi/ML) · injectable;intravenous | Ammonia N-13 | Rx |
| Aug 14, 2019 | Supplement 2Manufacturing · Standard review | Approved | None posted |
| Oct 30, 2014 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters